AATec Medical
Pioneering biotech solutions for inflammatory disorders, viral infections, and rare diseases with recombinant alpha-1 antitrypsin (AAT).
Pioneering biotech solutions for inflammatory disorders, viral infections, and rare diseases with recombinant alpha-1 antitrypsin (AAT).
AATec Medical is a pioneering biotech firm that focuses on developing solutions for inflammatory disorders, viral infections, and rare diseases using recombinant alpha-1 antitrypsin (AAT). The company's mission is to leverage the potential of AAT to address unmet medical needs in biotechnology and health care.
Recently, AATec Medical secured a significant $2.70M Seed Round investment on 17 July 2023. This funding will undoubtedly provide the company with the necessary resources to advance its research and development efforts, as well as expand its market reach.
With no specific headquarters mentioned, AATec Medical's innovative approach to utilizing AAT presents remarkable potential for disrupting the biotech and healthcare industries. The absence of disclosed investors signifies that the company may have chosen to keep this information private.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $2.70M | - | 17 Jul 2023 |
We care about your data, and we'd love to use cookies make your experience better.